Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2013, Article ID 436929, 7 pages
http://dx.doi.org/10.1155/2013/436929
Research Article

Hospitalization Rates and Discharge Status in Multiple Sclerosis

University of Pittsburgh Medical Center, Division of Gastroenterology, 200 Lothrop Dr., Pittsburgh, PA 15213, USA

Received 5 March 2013; Revised 15 April 2013; Accepted 22 April 2013

Academic Editor: Bianca Weinstock-Guttman

Copyright © 2013 Sanober Nusrat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Pittock, W. T. Mayr, R. L. McClelland et al., “Disability profile of MS did not change over 10 years in a population-based prevalence cohort,” Neurology, vol. 62, no. 4, pp. 601–606, 2004. View at Google Scholar · View at Scopus
  2. S. J. Pittock, W. T. Mayr, R. L. McClelland et al., “Change in MS-related disability in a population-based cohort: a 10-year follow-up study,” Neurology, vol. 62, no. 1, pp. 51–59, 2004. View at Google Scholar · View at Scopus
  3. K. M. Myhr, T. Riise, C. Vedeler et al., “Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension,” Multiple Sclerosis, vol. 7, no. 1, pp. 59–65, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bakke, K. M. Myhr, M. Gronning, and H. Nyland, “Bladder, bowel and sexual dysfunction in patients with multiple sclerosis—a cohort study,” Scandinavian Journal of Urology and Nephrology, Supplement, vol. 179, pp. 61–66, 1996. View at Google Scholar · View at Scopus
  5. A. Hennessey, N. P. Robertson, R. Swingler, and D. A. S. Compston, “Urinary, faecal and sexual dysfunction in patients with multiple sclerosis,” Journal of Neurology, vol. 246, no. 11, pp. 1027–1032, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Marrie, G. Cutter, T. Tyry, T. Vollmer, and D. Campagnolo, “Disparities in the management of multiple sclerosis-related bladder symptoms,” Neurology, vol. 68, no. 23, pp. 1971–1978, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Nusrat, E. Gulick, D. Levinthal et al., “Anorectal dysfunction in multiple sclerosis: a systematic review,” ISRN Neurology, vol. 2012, Article ID 376023, 2012. View at Publisher · View at Google Scholar
  8. A. Manack, S. P. Motsko, C. Haag-Molkenteller et al., “Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database,” Neurourology and Urodynamics, vol. 30, no. 3, pp. 395–401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Zorzon, R. Zivadinov, L. Monti Bragadin et al., “Sexual dysfunction in multiple sclerosis: a 2-year follow-up study,” Journal of the Neurological Sciences, vol. 187, no. 1-2, pp. 1–5, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Munteis, M. Andreu, M. J. Téllez, D. Mon, A. Ois, and J. Roquer, “Anorectal dysfunction in multiple sclerosis,” Multiple Sclerosis, vol. 12, no. 2, pp. 215–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability,” Neurology, vol. 50, no. 3, pp. 701–708, 1998. View at Google Scholar · View at Scopus
  12. G. Comi, M. Filippi, and J. S. Wolinsky, “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis,” Annals of Neurology, vol. 49, no. 3, pp. 290–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Google Scholar · View at Scopus
  14. L. Kappos, C. Polman, C. Pozzilli, A. Thompson, and F. Dahlke, “Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis,” The Lancet, vol. 352, no. 9139, pp. 1491–1497, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. G. C. Ebers, “Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis,” The Lancet, vol. 352, no. 9139, pp. 1498–1504, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. S. A. Rizvi and M. A. Agius, “Current approved options for treating patients with multiple sclerosis,” Neurology, vol. 63, supplement 12, pp. S8–S14, 2004. View at Google Scholar · View at Scopus
  17. A. E. Miller, P. O'Connor, J. S. Wolinsky et al., “Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis,” Multiple Sclerosis Journal, vol. 18, pp. 1625–1632, 2012. View at Google Scholar
  18. G. Comi, D. Jeffery, L. Kappos et al., “Placebo-controlled trial of oral laquinimod for multiple sclerosis,” The New England Journal of Medicine, vol. 366, pp. 1000–1009, 2012. View at Google Scholar
  19. B. Khatri, F. Barkhof, G. Comi et al., “Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study,” The Lancet Neurology, vol. 10, no. 6, pp. 520–529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Wundes, G. H. Kraft, J. D. Bowen, T. A. Gooley, and R. A. Nash, “Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting,” Clinical Neurology and Neurosurgery, vol. 112, no. 10, pp. 876–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. L. Rotstein, M. Mamdani, and P. W. O'Connor, “Increasing use of disease modifying drugs for MS in Canada,” Canadian Journal of Neurological Sciences, vol. 37, no. 3, pp. 383–388, 2010. View at Google Scholar · View at Scopus
  22. J. D. Prescott, S. Factor, M. Pill, and G. W. Levi, “Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database,” Journal of Managed Care Pharmacy, vol. 13, no. 1, pp. 44–52, 2007. View at Google Scholar · View at Scopus
  23. E. Frohman, T. Phillips, K. Kokel et al., “Disease-modifying therapy in multiple sclerosis: strategies for optimizing management,” Neurologist, vol. 8, no. 4, pp. 227–236, 2002. View at Google Scholar · View at Scopus
  24. M. Oleen-Burkey, A. Cyhaniuk, and E. Swallow, “Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years,” Journal of Medical Economics, vol. 16, no. 3, pp. 397–406, 2013. View at Google Scholar
  25. J. Margolis, R. Fowler, B. Johnson et al., “Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study,” BMC Neurology, vol. 11, article 122, 2011. View at Google Scholar
  26. C. W. Noonan, S. J. Kathman, and M. C. White, “Prevalence estimates for MS in the United States and evidence of an increasing trend for women,” Neurology, vol. 58, no. 1, pp. 136–138, 2002. View at Google Scholar · View at Scopus
  27. R. J. Buchanan, R. A. Martin, S. Wang, and H. Ju, “Analyses of nursing home residents with multiple sclerosis at admission and one year after admission,” Multiple Sclerosis, vol. 10, no. 1, pp. 74–79, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Calcagno, G. Ruoppolo, M. G. Grasso, M. De Vincentiis, and S. Paolucci, “Dysphagia in multiple sclerosis—prevalence and prognostic factors,” Acta Neurologica Scandinavica, vol. 105, no. 1, pp. 40–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. A. De Pauw, E. Dejaeger, B. D'hooghe, and H. Carton, “Dysphagia in multiple sclerosis,” Clinical Neurology and Neurosurgery, vol. 104, no. 4, pp. 345–351, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Annoni, H. Vuagnat, R. Frischknecht, and D. Uebelhart, “Percutaneous endoscopic gastrostomy in neurological rehabilitation: a report of six cases,” Disability and Rehabilitation, vol. 20, no. 8, pp. 308–314, 1998. View at Google Scholar · View at Scopus
  31. N. Grytten, J. H. Aarseth, K. Espeset et al., “Stoppers and non-starters of disease-modifying treatment in multiple sclerosis,” Acta Neurologica Scandinavica, vol. 127, pp. 133–140, 2013. View at Google Scholar
  32. A. Solari and D. Radice, “Health status of people with multiple sclerosis: a community mail survey,” Neurological Sciences, vol. 22, no. 4, pp. 307–315, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. W. T. Mayr, S. J. Pittock, R. L. McClelland, N. W. Jorgensen, J. H. Noseworthy, and M. Rodriguez, “Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000,” Neurology, vol. 61, no. 10, pp. 1373–1377, 2003. View at Google Scholar · View at Scopus
  34. H. Houzen, M. Niino, M. Hirotani et al., “Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan,” Journal of the Neurological Sciences, vol. 323, pp. 117–122, 2012. View at Google Scholar
  35. M. Kramer, N. van der Maas, E. van Soest et al., “Incidence of multiple sclerosis in the general population in the Netherlands, 1996–2008,” Neuroepidemiology, vol. 39, pp. 96–102, 2012. View at Google Scholar
  36. M. T. Wallin, W. J. Culpepper, P. Coffman et al., “The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service,” Brain, vol. 135, pp. 1778–1785, 2012. View at Google Scholar
  37. D. Kotzamani, T. Panou, V. Mastorodemos et al., “Rising incidence of multiple sclerosis in females associated with urbanization,” Neurology, vol. 78, pp. 1728–1735, 2012. View at Google Scholar
  38. K. A. Stolp-Smith, E. J. Atkinson, M. E. Campion, P. C. O'Brien, and M. Rodriguez, “Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN,” Neurology, vol. 50, no. 6, pp. 1594–1600, 1998. View at Google Scholar · View at Scopus
  39. S. M. Curkendall, C. Wang, B. H. Johnson et al., “Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy,” Clinical Therapeutics, vol. 33, no. 7, pp. 914–925, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Tan, Q. Cai, S. Agarwal, J. J. Stephenson, and S. Kamat, “Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis,” Advances in Therapy, vol. 28, no. 1, pp. 51–61, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Tan, J. Yu, D. Tabby, A. Devries, and J. Singer, “Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study,” Multiple Sclerosis, vol. 16, no. 8, pp. 956–963, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. M. Poser, D. W. Paty, and L. Scheinberg, “New diagnostic criteria for multiple sclerosis: guidelines for research protocols,” Annals of Neurology, vol. 13, no. 3, pp. 227–231, 1983. View at Google Scholar · View at Scopus
  43. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. D. B. Clifford, A. DeLuca, D. M. Simpson, G. Arendt, G. Giovannoni, and A. Nath, “Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases,” The Lancet Neurology, vol. 9, no. 4, pp. 438–446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. D. W. Brandes, T. Callender, E. Lathi, and S. O'Leary, “A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events,” Current Medical Research and Opinion, vol. 25, no. 1, pp. 77–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Romley, D. Goldman, M. Eber et al., “Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis,” American Journal of Managed Care, vol. 18, no. 8, pp. 460–464, 2012. View at Google Scholar
  47. K. J. Aronson, “Quality of life among persons with multiple sclerosis and their caregivers,” Neurology, vol. 48, no. 1, pp. 74–80, 1997. View at Google Scholar · View at Scopus
  48. L. I. Iezzoni, S. R. Rao, and R. P. Kinkel, “Experiences acquiring and using mobility aids among working-age persons with multiple sclerosis living in communities in the United States,” American Journal of Physical Medicine & Rehabilitation, vol. 89, no. 12, pp. 1010–1023, 2010. View at Google Scholar · View at Scopus
  49. S. Twork, I. Nippert, P. Scherer, J. Haas, D. Pöhlau, and J. Kugler, “Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population,” Current Medical Research and Opinion, vol. 23, no. 6, pp. 1209–1215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Shirani, Y. Zhao, E. Kingwell et al., “Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009),” Multiple Sclerosis International, vol. 18, pp. 442–450, 2012. View at Google Scholar
  51. R. B. Forbes, A. Lees, N. Waugh, and R. J. Swingler, “Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis,” British Medical Journal, vol. 319, no. 7224, pp. 1529–1533, 1999. View at Google Scholar · View at Scopus
  52. R. Sánchez-de la Rosa, E. Sabater, M. A. Casado et al., “Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients,” Journal of Medical Economics, vol. 15, pp. 424–433, 2012. View at Google Scholar
  53. L. D. Goldberg, N. C. Edwards, C. Fincher, Q. V. Doan, A. Al-Sabbagh, and D. M. Meletiche, “Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis,” Journal of Managed Care Pharmacy, vol. 15, no. 7, pp. 543–555, 2009. View at Google Scholar · View at Scopus